Interestingly, a mutation of KRAS indeed affects the response to EGFR inhibitor56, while the efficacy of TKI258 in colorectal cancer is not dependent on the mutation status of KRAS we do find a connection in the DCA results57, indicating a possibly distinct effect of KRAS mutation status on TKI258 efficacy in other types of cancer. This evidence concerns the gene EGFR and cancer.